Incyte Corp
(NAS:INCY)
$
69.91
0.07 (0.1%)
Market Cap: 13.47 Bil
Enterprise Value: 11.73 Bil
PE Ratio: 499.36
PB Ratio: 4.25
GF Score: 89/100 Incyte Corp at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 16, 2020 / 01:30PM GMT
Release Date Price:
$89.94
(-1.63%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
Okay. Great. Welcome, everyone. My name is Vikram Purohit. I'm one of the biotech analysts with Morgan Stanley Research, and we are here for a fireside chat with the management team from Incyte. I have on the line with me Hervé Hoppenot and Christiana Stamoulis, CEO and CFO of Incyte. Welcome to both of you.
HervÃ;Hoppenot
Incyte Corporation - Chairman, President & CEO
© -
Thank you. Good morning.
Christiana Stamoulis
Incyte Corporation - Executive VP & CFO
Good morning, Vikram.
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst
Good morning. Before we go ahead and get started with the discussion, I need to read a brief disclaimer. Please note that this webcast is for Morgan Stanley's clients and appropriate Morgan Stanley employees only. This webcast is not for members of the press. If you are a member of the press, please disconnect and reach out separately. For
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot